免疫检查点抑制剂在肿瘤免疫治疗中的现状要点分析.pptVIP

Story of Anti-CTLA-4(Ipilimumab) ?intravenous infusions of 10 mg/kg?ipilimumab?or placebo every 3 weeks for four doses, then every 3 months for up to 3 years. 951 stage III cutaneous melanoma with adequate resection of lymph nodes ?ipilimumab (n=475) or placebo (n=476) Story of Anti-CTLA-4(Ipilimumab) Story of Anti-CTLA-4(Ipilimumab) Clinical trials: Non-small-cell lung cancer Prostage cancer Extensive-disease-small-cell lung cancer . . . . PD-1 (CD279) Member of Ig superfamily Inducible expression on T or B cell Deliver inhibition signal Story of B7-H1/PD-1 PD-L1 (